Left ventricular thrombus
- 639 Downloads
Left ventricular thrombus (LVT) is a frequent complication in patients with acute anterior myocardial infarction (MI) and in those with dilated cardiomyopathy (DCM). The clinical importance of LVT lies in its potential to embolize. The current treatment of patients with acute MI centers on reperfusion, and although controversial, the incidence of LVT complicating acute anterior MI is probably reduced when compared with historical controls. Nevertheless, stroke continues to be a clinically important complication of acute MI and is most common in patients with anterior MI, in part secondary to embolization of LVT. Therapeutic anticoagulation during acute MI reduces the incidence of LVT, and long-term anticoagulation has been associated with a reduction in recurrent infarction and ischemic stroke, but carries hemorrhagic risk. Primary treatment strategies for patients with acute MI center on reperfusion therapy followed by antiplatelet agents and pharmacologic blockade of abnormal neurohumoral mechanisms. Strategies to prevent stroke following infarction include risk stratification for development of LVT and embolism. For patients with anterior MI, particularly those with apical akinesis or dyskinesis, therapeutic anticoagulation reduces the number of LVT and cardioembolic strokes. However, the absolute number of ischemic strokes prevented with this strategy may only be marginal, given the anticoagulation risk, particularly if antiplatelet agents are used concurrently. An attractive alternative strategy is echocardiographic evaluation following anterior infarction with therapeutic anticoagulation reserved for those with demonstrable thrombus. The efficacy of this strategy, however, never has been proven in a clinical study. Primary prevention of cardioembolic stroke through therapeutic anticoagulation is controversial in patients with DCM; the greatest benefit would be expected for those with severe left ventricular dysfunction. If LVT is detected during the course of MI or DCM, therapeutic anticoagulation is usually indicated with the expectation that the majority of thrombi will resolve without clinical evidence of systemic embolism. Additional therapeutic intervention is rarely needed.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Keren A, Goldberg S, Gottlieb S, et al.: Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction. J Am Coll Cardiol 1990, 15:790–800. The authors describe the natural history of LVT following acute MI in 198 consecutive patients, 34 of whom received thrombolytic therapy. This large series of patients was prospectively followed with echocardiography for an average of 2 years following infarction. Anterior infarction, ejection fraction less than or equal to 35%, and apical dyskinesis were predictive of LVT development. Nearly half of the patients with thrombus had resolution of thrombus 6 months after infarction. Resolution of thrombus was associated with akinesia rather than dyskinesia at hospital discharge and warfarin treatment. LVT developed after discharge in about 10% of patients and was related to deterioration in left ventricular function, ejection fraction less than or equal to 35% before discharge, and ventricular aneurysm or dyskinesia. These observations have established the natural history of LVT and provide the rational for anticoagulation therapy recommendations.PubMedCrossRefGoogle Scholar
- 8.Ryan TJ, Antman EM, Brooks NH, et al.: 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999, 34:890–911. This committee recommends a conservative anticoagulation approach to the prevention of stroke, presumably due to embolism of LVT, following acute MI. The authors reserve long-term anticoagulation to patients with documented LVT complicating acute MI.PubMedCrossRefGoogle Scholar
- 9.Cairns JA, Theroux P, Lewis HD Jr, et al.: Antithrombotic agents in coronary artery disease. Chest 1998, 114:611S-633S. This Consensus Panel on Antithrombotic Therapy of the ACCP recommends a more aggressive approach to anticoagulation following acute MI that than of the ACC/AHA guidelines. Anticoagulation is recommended for those with large anterior infarction, apical akinesis or dyskinesis, and moderate or worse left ventricular dysfunction.PubMedGoogle Scholar
- 11.Anticoagulants in the secondary prevention of events in coronary thrombosis (ASPECT) research group: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994, 343:499–503.Google Scholar
- 15.Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. The SCATI (Studio Sulla Calciparina Nell’Angina E Nella Trombosi Ventricolare Nell’Infarto) Group. Lancet 1989:182-186.Google Scholar
- 16.Kontny F, Dale J, Abildgaard U, et al.: Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) study. J Am Coll Cardiol 1997, 30:962–969.PubMedCrossRefGoogle Scholar